PART B - FEE(S) TRANSMITTAL

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

SUGHRUE MION, PLLC 2100 PENNSYLVANIA AVENUE, NW SUITE 800 WASHINGTON, DC 20037 Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

APPLICATION NO. FILIN		IG DATE	FIRST NAMED INV			NTOR ATTORNEY D		OCKET NO. C		CONFIRMATION NO.	
		5/2004		Yumiko UNO			Q101072			8263	
10/001,000											
TITLE OF INVENTION: HUMAN SODIUM-DEPENDENT BILE ACID TRANSPORTER PROTEINS											
APPLN, TYPE	SMALL ENTITY	ISSUI	E FEE	PUBLICATION FEE		PREV. PAID ISSUE FEE		TOTAL FEE(S) DUE		DATE DUE	
nonprovisional	NO	NO \$1510.00		\$300.00		\$	0.00	\$1,810.00		05/23/2010	
EXAMINER			ART UNIT C		CLASS-	SS-SUBCLASS			,		
Jon	1647		530-	350000							
1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363 2. For printing on the patent front page list 1 Sughrue Mion, PLLC											
☐ Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.						(1) the names of up to 3 registered patent attorneys or agents OR, alternatively, 2					
☐ "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) ATTACHED. Use of a Customer Number is required. (2) the name of a single firm (having as a member a registered attorney or agent) and the 3											
names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be											
printed.											
3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)											
PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.											
(A) NAME OF ASSIGNEE (B) RESIDENCE: (CITY and STATE OR COUNTRY)											
TAKEDA PHARMACEUTICAL COMPANY LIMITED Osaka, Japan											
Please check the appropriate assignee category or categories (will not be printed on the patent): 🗆 Individual 🗅 Corporation or other private group entity 🗅 Government											
4a. The following fee(4b. Payme	4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)									
☑ Issue Fee					☐ A check is enclosed.						
☑ Publication Fee (No	☐ Paymer	☐ Payment by credit card. Form 1310-2038 is attached.									
☐ Advance Order - #	overpayme	☑ The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number 19-4880.									
				☑ The US 19-4880.	SPTO is Please a	s directed an also credit an	d authorized to only overpayments	charge all requi to said Deposit	red f	ees to Deposit Account No.	
5. Change in Entity St	atus (from status in	dicated above)								
☐ a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. ☐ b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).											
The Director of the US	SPTO is requested to	apply the Iss	ue Fee and P	ublication Fee (if any)	or to re-apply	any previously	paid issue fee to	the	application identified above.	
NOTE: The Issue Fee party in interest as sho	and Publication Fe	e (if required)	will not be a	accepted from a	nyone o	ther than the	applicant; a reg	istered attorney	or ag	gent; or the assignee or other	
Authorized Signature Musbul Dungth					Date			May 2	May 21, 2010		
Typed or Printed Nan	V I	Registration No.			36,787						
Modified PTOL-85 (I	Rev. 08/08 Approve	d for use thro	ugh 08/31/20	10.							